Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Hantschel

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Genes & Cancer|December 11, 2012
Structure, regulation, signaling, and targeting of abl kinases in cancerOliver Hantschel
Blood|February 28, 2015
Targeting BCR-ABL and JAK2 in Ph+ ALLOliver Hantschel
Nature Chemical Biology|February 16, 2024
The druggability of SH2 domains unmaskedOliver Hantschel
Swiss Medical Weekly|November 30, 2017
Monobodies as possible next-generation protein therapeutics - a perspectiveOliver Hantschel
Hemasphere|March 21, 2022
Chronic myeloid leukemiaOliver Hantschel
Haematologica|February 3, 2012
Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistanceOliver Hantschel
ACS Chemical Biology|December 23, 2014
Unexpected off-targets and paradoxical pathway activation by kinase inhibitorsOliver Hantschel
Blood|May 1, 2020
CDK6 degradation hits Ph+ ALL hardOliver Hantschel
Chimia|April 8, 2016
2016 International Symposium on Chemical Biology of the NCCR Chemical Biology Campus Biotech, Geneva 13-15.1.2016Oliver Hantschel, Beat Fierz
Structure (London, England : 1993)|June 4, 2015
Kinase Regulation in Mycobacterium tuberculosis: Variations on a ThemeSina Reckel, Oliver Hantschel
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Genes & Cancer|December 11, 2012
Structure, regulation, signaling, and targeting of abl kinases in cancerOliver Hantschel
Blood|February 28, 2015
Targeting BCR-ABL and JAK2 in Ph+ ALLOliver Hantschel
Nature Chemical Biology|February 16, 2024
The druggability of SH2 domains unmaskedOliver Hantschel
Swiss Medical Weekly|November 30, 2017
Monobodies as possible next-generation protein therapeutics - a perspectiveOliver Hantschel
Hemasphere|March 21, 2022
Chronic myeloid leukemiaOliver Hantschel
Haematologica|February 3, 2012
Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistanceOliver Hantschel
ACS Chemical Biology|December 23, 2014
Unexpected off-targets and paradoxical pathway activation by kinase inhibitorsOliver Hantschel
Blood|May 1, 2020
CDK6 degradation hits Ph+ ALL hardOliver Hantschel
Chimia|April 8, 2016
2016 International Symposium on Chemical Biology of the NCCR Chemical Biology Campus Biotech, Geneva 13-15.1.2016Oliver Hantschel, Beat Fierz
Structure (London, England : 1993)|June 4, 2015
Kinase Regulation in Mycobacterium tuberculosis: Variations on a ThemeSina Reckel, Oliver Hantschel
Pageof 8